Arginine inactivation of viruses
    1.
    发明授权
    Arginine inactivation of viruses 有权
    精氨酸灭活病毒

    公开(公告)号:US08980610B2

    公开(公告)日:2015-03-17

    申请号:US13130540

    申请日:2009-11-20

    IPC分类号: C12N7/06 C12N7/00 A61K39/21

    摘要: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.

    摘要翻译: 本发明涉及使用精氨酸灭活或降低可能存在于由真核细胞(例如抗体或其它治疗性蛋白质)产生的生物组合物中的包膜病毒的感染滴度的方法。 在一些实施方案中,通过暴露于精氨酸的病毒滴度的灭活或还原在中性(pH〜7)或接近中性(〜pH 6〜〜8H)环境中实现。

    Arginine Inactivation of Viruses
    2.
    发明申请
    Arginine Inactivation of Viruses 有权
    精氨酸灭活病毒

    公开(公告)号:US20120015424A1

    公开(公告)日:2012-01-19

    申请号:US13130540

    申请日:2009-11-20

    IPC分类号: C12N7/06 C07K16/00

    摘要: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.

    摘要翻译: 本发明涉及使用精氨酸灭活或降低可能存在于由真核细胞(例如抗体或其它治疗性蛋白质)产生的生物组合物中的包膜病毒的感染滴度的方法。 在一些实施方案中,通过暴露于精氨酸的病毒滴度的灭活或还原在中性(pH〜7)或接近中性(〜pH 6〜〜8H)环境中实现。